uploads/2018/05/Chart-07-1.jpg

How Merck’s Animal Health Segment Did in 1Q18

By

Updated

Animal Health segment

In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million, including 7% revenue growth at constant exchange rates and a 6% boost by foreign exchange.

Article continues below advertisement

Revenue

The above chart shows Merck’s Animal Health revenue since 1Q17. Animal Health revenue grew in 1Q18 due to strong sales of livestock products, including ruminants and poultry products, and companion animal products, including Bravecto and vaccines.

Merck’s livestock products include products acquired from Vallée in 2017, and aquaculture, swine, and poultry products. Vallée’s portfolio included parasiticides, anti-infectives, and vaccines for livestock, horses, and companion animals. Merck’s aquaculture products, which maximize fish growth and survival and farmed fish production, include Aquavac, Aquaflor, and Slice. Merck’s swine products include Regumate, Respig, and Zuprevo.

Merck’s companion animal portfolio includes various pet products for owners and veterinarians. The Bravecto line, which includes chewable tablets used to kill fleas and ticks in dogs and cats for up to 12 weeks, is among Merck’s key Animal Health products. Merck’s other companion animal products include its Nobivac Canine Flu Bivalent Vaccine, Activyl, Panacur, Scalibor, and veterinary insulin Vetsulin. The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 4.5% of its total investments in Merck, 8.2% in Pfizer (PFE), 6.6% in Bristol-Myers Squibb (BMY), and 4.3% in Eli Lilly (LLY).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

Advertisement

More From Market Realist